|
|
|
|
|
|
|
||||||
|
Alternative Cancer Therapy Protocol Recommended
Products EXAMPLES OF PATIENT REPORTS FROM THE CENTER: Pancreatic cancer:
A woman presented at the clinic with a very large pancreatic mass with
metastasis to the liver. During earlier surgery, a biopsy identified
a poorly differentiated adenocarcinoma at the head of the pancreas.
The liver was described as full of tumors, rock-hard, and palpable at
the level of the umbilicus (or navel). Dr. Riordan began an IV of vitamin
C and pancreatic enzymes. At the 2-month interval, although the woman
was alive, the tumors showed no signs of regression. At that time, Bindweed
was added to the protocol. Within 8 days, the tumor felt softer to the
touch, and within a couple of weeks, the tumor shrinkage was dramatic.
Simultaneously, laboratory values dramatically improved. Bilirubin reduced
from 18 mg/dL-1.2 mg/dL. Liver enzymes and gamma-glutamyl transpeptidase
(GGT) became normal after being in the thousands. The woman's edema
disappeared and the tumorous mass showed a 90% reduction. At last account,
the woman continued to do well using Bindweed, MPGC, and pancreatic
enzymes. Oral doses of Bindweed displayed no acute toxicity at 20,000 mg/kg (well above the therapeutic range); MPGC showed no acute toxicity at amounts > 5000 mg/kg. Although these products display extremely low toxicity profiles, this regime should be used with the supervision of a physician. Because of angiogenesis inhibition, pregnant and nursing women, as well as patients with active wounds or heart disease, should especially heed this advice. Various inflammatory conditions, such as autoimmune problems, could possibly be made worse by supplementation. It is suggested that patients discontinue Bindweed 2 weeks before and after surgery. These products can be purchased from Aidan, Inc., by telephone at (800) 529-0269. Bindweed is sold as C-Statin and MPGC is sold as ImmKine. (A tape authenticating material presented is available at Allergy Research, [800] 545-9960.)
Antineoplaston
Therapy, a Therapy Unique to the Burzynski Clinic Reducing a remarkably complex disease to one of simplistic nature, cancer occurs when genes that regulate cell growth become dysfunctional. For example, oncogenes (genes involved in cell growth and proliferation) and tumor suppressor genes (genes that turn off replicative mechanisms) lose their biological savvy. With cell division upregulated and tumor suppressor activity downgraded, cancer is in control. Antineoplastons, the core of the Burzynski program, reestablish cellular control by squelching rampant cell division and awakening a lax tumor suppressor gene. With the cells' replicative patterns restored, the tumor typically shrinks and (in some cases) dies. Ras oncogenes are involved in the genesis of approximately 40% of all cancers. The simplest anti-neoplaston (phenylacetate) is capable of turning off the signal sent by Ras oncogenes, curtailing the constant multiplication of malignant cells. It appears phenylacetate also regulates the activity of p53, a tumor suppressor gene (Bland/Burzynski 1998) (please refer to the protocol on Cancer Treatment: The Critical Factors to learn more about Ras oncogenes, as well as tumor suppressor genes). Unlike traditional therapies that kill both healthy and diseased cells, antineoplastons have no significant side effects. The intent of antineoplastons is not to poison the cell, but rather to restore genetic awareness, normalizing cell growth. The banner of natural medicine has always been to treat the cause of the disease, not the result; this is precisely the logic behind antineoplaston therapy. The Burzynski protocol is safe enough to be given to patients 24 hours a day. The therapy is delivered intravenously through a catheter inserted in a central venous line. A pump infuses the medications at scheduled intervals, with the dose and dosing schedule dependent upon the type of cancer. The pump and the therapy bags are small and light enough to be carried around by even a young child. The length of treatment depends on the patient's response. When patients achieve a complete response of long duration, IV therapy is discontinued and the therapy is then administered in capsule form for an additional 8-12 months. Dr. Burzynski (of international renown) has particular success with non-Hodgkin's lymphoma, as well as two brain cancers: glioblastoma multiforme and astrocytoma, both extremely difficult to control using conventional therapy. A noteworthy study showed that patients with brain tumors had a rate of survival and complete and partial remissions 7 times greater than successes recorded to surgery, radiation, or chemotherapy. As an example, a clinical trial of mixed glioma showed that half of the patients responded to antineoplastons. (Patients had to have at least a 50% reduction in the size of their tumors to count as responders.) Twenty-five percent of those numbers saw their tumor disappear completely although conventional chemotherapy is virtually helpless against this type of cancer (Mouscher 1997). Although many patients attest to their good health because of antineoplaston therapy, Dr. Burzynski is forced to engage in degrading wars with the FDA and the Texas Medical Society, as well as snubs from the American Cancer Society and the National Cancer Institute. Because of the politics of medicine, nontraditional oncologists face an ongoing struggle that proves their professional and personal worth. BURZYNSKI
CLINIC GONZALEZ CANCER THERAPY Proteolytic
Enzymes--Diet, Supplements, and Detoxification Various scientists/physicians have devoted the entirety of their professional careers searching for nontoxic solutions to cancer. Instead of being heralded for their incredible commitment and personal sacrifice, accusations have often been threatening and accusing. Individuals of lesser stature would have abandoned their vision, but a medical martyr stays the course. Dr. Nicholas Gonzalez, a graduate of Cornell Medical College with postgraduate training at Vanderbilt University, has (after countless personal attacks) emerged on stronger footing than at any time in his committed career. The once castigated oncologist is now in demand, and doctors at one time hostile to his treatment (on occasion) refer patients and family members for his help. Dr. Gonzalez shares his concept of treating cancer with several pioneers, that is, Robert Beard (a Scottish embryologist), Francis Marion Pottenger (who in 1919 authored Symptoms of Visceral Disease, a landmark contribution describing the activities of the autonomic nervous system), and William Donald Kelley, a Texas orthodontist who (using Beard/Pottenger logic) developed a remarkably successful nutritional and metabolic approach to treat cancer. Kelley treated himself for nondiagnosed pancreatic cancer and 20 years hence was applying the same principles, caring for hundreds of terminally ill patients. Dr. Gonzalez, inherently interested in the nutrition/cancer link, was invited to investigate Dr. Kelley's files. Perusing the case histories of more than 1000 patients and contacting scores of those numbers, Dr. Gonzalez discovered that hundreds of patients (with terminal disease) were alive 5, 10, and 15 years following diagnosis. The men (Kelley and Gonzalez) were at opposite ends of their careers. Kelley's work had not been accepted by orthodoxy; in fact the therapy was denounced by the American Cancer Society and put on the unproven-methods blacklist. Constantly castigated, stripped of his license, and weary, he renounced his practice and fled Texas. Dr. Gonzalez, young and bedecked with impeccable credentials (merits Kelley lacked), enthusiastically opened his own office in Manhattan in the late 1980s. Dr. Gonzalez and Dr. Linda Isaacs (a cophysician), wanting to validate the therapy, compared the outcome of 11 of their patients with inoperable Stage II-IV pancreatic adenocarcinoma to similar patients, who were treated with conventional therapies. Typically, only about 20% of patients with pancreatic cancer survive 1 year, with statistics dropping dramatically thereafter. In a trial using gemcitabine, a costly and debilitating drug, of 126 subjects, not a single patient lived longer than 19 months. Patients adhering to the Gonzalez program responded far better, and in 1999 he and Isaacs published their data in the peer-reviewed journal Nutrition Cancer (Gonzalez et al. 1999). Although the numbers involved in the study were small, the results were unmistakably impressive: 9 survived 1 year; 5 lived 2 years; 4 survived 3 years; 2 lived 4 years; and 1 survived almost 5 years. The strength of the Gonzalez/Isaacs study led to a large-scale NCI/NIH funded clinical trial (a 5-year $l.4-million study) conducted by the Columbia Presbyterian Medical Center. This study will compare the effectiveness of a nutritional approach against gemcitabine in patients with advanced pancreatic cancer. The study has full FDA, IND (Investigational New Drug) approval. Half of the participants will receive the best drugs and hospital care available and will be treated by Dr. John Chabot, chief of surgical oncology at Columbia. The others will be placed on the nutritional/metabolic regime and supervised by Drs. Gonzalez and Isaacs. Patients are allowed to choose which treatment they prefer (natural or conventional), but to date it has been difficult to interest patients in enrolling in the chemotherapeutic group: 200 patients inquired and 197 refused the 50% chance of randomization to the chemotherapy arm. A nutritional/metabolic approach to treating cancer is nontoxic and (though rigorous) does not compare to the stress of conventional compliance. The Gonzalez program requires an aggressive number of daily supplements (130-160 capsules). The pancreatic enzymes (central to the treatment), vitamins, minerals, amino acids, and antioxidants are normally taken for 15 days, then flushed from the system for 5 days, and then started anew. Coffee enemas, liver flushes, and a whole-body purge with psyllium husks, which Dr. Gonzalez calls "the clean sweep," are essential to the success of the program. It appears that critics have singled out the coffee enemas as the area of greatest contention. Dr. Gonzalez depends upon coffee enemas (detoxification) to assist the body in processing enormous amounts of toxic debris that can be produced as tumors break down. Few are aware that from 1899-1977 coffee enemas were included in the Merck Manual, a compendium of orthodox research techniques. Coffee enemas were not removed from the Manual because of their ineffectiveness, but rather to make room for newer material. One of the many nutritional therapies utilized by Dr. Gonzalez is proteolytic enzymes. Scientific and clinical studies corroborate the benefits of enzymes in the maintenance of good health and the management of age-related frailties. For example, researchers in Austria found that enzymes help maintain healthy levels of transforming growth factor-beta (TGF-beta). TGF-beta, plays an important role in the body's ability to repair and heal itself, but excessive levels of TGF-beta, trigger abnormal growths that can give rise to cancer. Drs. Lucia Desser (Institute for Cancer Research, University of Vienna) and Karl Ransberger (Mucos Pharma, Munich, Germany) studied the effect of enzymes on TGF-beta, and found that pancreatic enzymes consistently brought levels back into the normal range (Blobe et al. 2000). Proteolytic enzymes also reduce the stickiness of cancer cells and the incidence of metastasis. The sticky nature of cancer is thought to be initiated by an enzyme deficiency, resulting in excessive fibrin production, a protein having the nature of barbed wire. Fibrin performs another task that strongly favors the tumor. As fibrin forms on the tumor cell membrane, it cloaks the tumor in a protective barrier, making tumor recognition extremely difficult. The close relationship between fibrin deposits, invasive tissue growth, and metastasis is well documented and generally accepted. For example, the European Journal of Cancer reported on the adhesiveness of cancer cells in the article "No Grip, No Growth" (Reijerkerk et al. 2000). Overcoming the inherent traits of cancer (cell adhesion or stickiness, migration, proliferation, and survival) are functions specific to proteolytic enzymes. Proteolytic enzymes are powerful anti-inflammatories. The Life Extension Foundation has been deliberate, instructing members that systemic inflammation is instrumental in initiating most cancers. The endo-thelium of tissue displaying inflammatory alterations (a thickened layer of adhesion molecules) is a site for metastasis. As proteolytic enzymes reduce inflammation, the risk of metastasis is further reduced. The literature (largely) shows that proteolytic enzyme therapy extends survival (from months to years) in patients with both bloodborne and hard tumors (NewsEdge 2000). Dr. Gonzalez accepts postchemotherapy patients, but the nutritional/metabolic program is not implemented in tandem with other treatments. For further information or to determine eligibility for a trial, contact Michelle Gabay, R.N., at (212) 305-9468 or visit the Gonzalez Web site . (Dr. Gonzalez treats all types of cancers; pancreatic cancer was selected for ongoing trials because of the deadliness of the malignancy.) Alternative Cancer Therapy Protocol Pg (1) (2) (3)
|
||||||
 |
||||||
|
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease
|
||||||
